ProPhase Labs Inc (PRPH)
ProPhase Labs Inc. is a healthcare company listed on OTC Markets under the ticker PRPH. The company operates as a common equity security and focuses on developing and commercializing novel drugs, dietary supplements, and related compounds in the United States. Its business is organized into two segments: Diagnostic Services and Consumer Products.
Within consumer products, ProPhase Labs markets TK-branded dietary supplements, including Legendz XL for male sexual enhancement and Triple Edge XL for energy and stamina support. In diagnostics, the company provides COVID-19-related clinical testing services, such as PCR tests for COVID-19 and Influenza A and B, along with rapid antigen testing. It also works on genomic testing technologies, the BE-Smart Esophageal Pre-Cancer screening test, and product candidates including LB-1 and LB-2 for potential applications in cancer, inflammatory diseases, and memory-related conditions. Founded in 1989 and headquartered in Garden City, New York, the company was previously known as The Quigley Corporation.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-PRPH
|
$0.077
|
28.5% Upside
|
Undervalued
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
0.0x
|
-1.6x
|
0.3x
|
980.433 K
|
9.861 M
|
90.1%
|
97.6%
|
-4.7
|
—
|
23.7%
|
